AUPH Q3 2022 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M+280.3% YoY

Gross Profit

$53M95.6% margin

Operating Income

-$9M-17.0% margin

Net Income

-$9M-16.1% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+97.9%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$488M

Total Liabilities

$65M

Stockholders' Equity

$423M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$15M	+280.3%
Gross Profit	$53M	$14M	+270.0%
Operating Income	-$9M	-$50M	+81.1%
Net Income	-$9M	-$50M	+82.1%

Revenue Segments

License

$30M54%

Product

$26M46%